Almost overnight, COVID-19 transformed the delivery of cancer care in the U.S. as payers and providers mobilized to balance a highly vulnerable population’s risk of exposure with the need to continue effective care. As a leader in oncology specialty risk management, New Century Health discussed the impact on cancer care to-date and the anticipated long-term effects on treatment and outcomes.
In this webinar, we explore the significant—and likely lasting—impact of COVID-19 on oncology, including:
- Changes in the delivery of cancer care. COVID-19 has dramatically altered the way patients with cancer receive care. Utilization trends have changed, prior-authorization requirements have been relaxed, and practices are working to deliver care in new ways that minimize patient exposure and risk.
- The downstream impact of delayed routine screenings. Across the nation, routine cancer screenings (e.g., mammograms, colonoscopies) have been delayed and cancelled to help stop the spread of COVID-19. This could have a long-lasting and potentially detrimental effect on cancer prevalence, disease progression at diagnosis, and survival rates.
- How health plans can respond. As the pandemic subsides, the need to rely on clinical evidence to guide care regimens will be increasingly important as the margin for error on treatment recommendations will become even smaller.
Jeffery Ward, MD
Oncologist/Hematologist, Swedish Cancer Institute
Andrew Hertler, MD
Chief Medical Officer, New Century Health
Anita Cattrell, PhD
Chief Innovation Officer, New Century Health
Senior Vice President, New Century Health